Eyelash Trichomegaly Secondary to Panitumumab Therapy

Luc G.T. Morris; H.S. Hochster; M.D. DeLacure

doi:10.3747/co.v18i3.762

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Case Report

1 June 2011

Eyelash Trichomegaly Secondary to Panitumumab Therapy

and

Head and Neck Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10022, USA

New York University Cancer Institute, New York University School of Medicine, New York, NY, USA

Author to whom correspondence should be addressed.

Curr. Oncol.2011, 18(3), 145-146;https://doi.org/10.3747/co.v18i3.762

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We report a recently encountered toxicity of therapy targeting the epidermal growth factor receptor (EGFR) that may be of interest to the wider community of oncologists. [...]

Keywords:

Panitumumab; epidermal growth factor receptor; trichomegaly; eyelash; hair; targeted therapy

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Canadian Initiatives for Locally Advanced Breast Cancer Research and Treatment: Inaugural Meeting of the Canadian Consortium for LABC

A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain